DGX Stock

Is Quest Diagnostics (DGX) a strong choice for momentum investors? Let's take a closer look.

On Thursday, Quest Diagnostics (NYSE: DGX) stock was close to reaching its highest value ever, which is impressive for a company that has been listed for many years. By late afternoon, the healthcare testing company's shares had risen over 5%, significantly outperforming the S&P 500 index, which was up by 0.8%. During this period, Quest reported a revenue of $2.62 billion, showing a strong year-over-year growth of almost 15%.

SECAUCUS, N.J., Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a top provider of diagnostic information services, has been recognized by Fortune® magazine as one of the 2025 World's Most Admired Companies™. This marks the 11th year in a row that the company has made it onto this prestigious list of respected global businesses.

On Thursday, Quest Diagnostics (DGX 5.49%) stock was close to reaching its highest price ever, which is impressive for a company that has been listed for many years. By late afternoon, the healthcare testing company's shares had risen over 5%, significantly outperforming the S&P 500 index, which was up by 0.8% at the same time.

Quest Diagnostics Incorporated (NYSE:DGX) will hold its Q4 2024 Earnings Conference Call on January 30, 2025, at 8:30 AM ET. The call will feature company leaders, including President & CEO Jim Davis and EVP & CFO Sam Samad. Various analysts from different firms will also participate in the discussion.

Quest Diagnostics (DGX 6.36%), a top company in diagnostic testing and information services, announced its fourth quarter results on January 30. The company had a strong quarter, with adjusted earnings per share (EPS) of $2.23, which was higher than the analysts' estimate of $2.18.

Quest Diagnostics (DGX) reported quarterly earnings of $2.23 per share, which is higher than the Zacks Consensus Estimate of $2.19 per share. This is an increase compared to earnings of $2.15 per share from the same period last year.

In the fourth quarter, Quest Diagnostics reported revenues of $2.62 billion, which is a 14.5% increase compared to 2023. The diluted earnings per share (EPS) for the quarter were $1.95, up 14.7% from the previous year, while the adjusted diluted EPS was $2.23, rising by 3.7%. For the full year, the company achieved revenues of $9.87 billion, a 6.7% increase, and expects the reported diluted EPS for 2025 to be between $8.34 and $8.59.

Doctors and patients will gain from Quest's top-quality test options and extensive health plan connections in Ohio. Quest Diagnostics, a major provider of diagnostic services, has announced that it has finished acquiring certain assets from University Hospitals, a prominent nonprofit health system and academic medical center in the U.S. This acquisition was previously announced and is now complete.